添加
<img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/>
作为您在 Google 上的首选新闻来源
<img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/>
立即添加
多个医疗保健和生物技术公司在周五的盘后交易中出现显著涨幅，动力来自临床更新、近期公告和技术反弹。
Kymera Therapeutics Inc. (KYMR) 在盘后交易中飙升至 73.00 美元，较收盘上涨 9.58%。该股在常规交易时段以 66.62 美元收盘，微幅上涨 0.59%。该公司准备在 12 月 8 日（周一）公布其口服 STAT6 降解剂 KT-621 在中重度特应性皮炎的 BroADen 1b 期临床试验的结果。对这一结果的期待似乎推动了强劲的盘后动能。
Ocular Therapeutix Inc. (OCUL) 的股价在盘后上涨至 14.00 美元，涨幅为 11.29%。该股在白天以 12.58 美元收盘，上涨 1.21%。虽然周五没有发布新的更新，但该公司最近宣布在非增殖性糖尿病视网膜病变的 AXPAXLI (OTX-TKI) 的 HELIOS-3 3 期注册项目中取得进展，第一位患者于 11 月 24 日被随机分配。
Guardian Pharmacy Services Inc. (GRDN) 的股价在盘后交易中上涨至 30.54 美元，涨幅为 2.62%。该股在白天以 29.76 美元收盘，上涨 1.50%。该公司周五没有发布新的更新，但该股在晚间交易中延续了上涨趋势。
Predictive Oncology Inc. (POAI) 的股价在盘后上涨至 4.84 美元，涨幅为 13.62%，此前在常规交易中大幅下跌，股价跌至 4.26 美元，跌幅超过 22%。本周早些时候，该公司披露已重新符合纳斯达克的最低股东权益要求，确保在纳斯达克资本市场的持续上市。盘后交易的反弹表明在合规更新后信心恢复。
Acumen Pharmaceuticals Inc. (ABOS) 的股价在盘后小幅上涨至 1.92 美元，涨幅为 3.23%。该股在白天以 1.86 美元收盘，下跌 6.06%。该公司最近在阿尔茨海默病临床试验会议（CTAD）上展示了新研究，强调通过转铁蛋白受体通路改善 AßO 靶向抗体的递送。与 JCR Pharmaceuticals 的合作工作正在向临床测试推进，支持长期发展前景。
EUDA Health Holdings Ltd. (EUDA) 的股价在盘后上涨至 2.93 美元，涨幅为 7.72%。该股在白天以 2.72 美元收盘，下跌 6.85%。在 11 月 26 日，该公司宣布与 Streeterville Capital 达成一项价值 100,000 美元的可转换认股权证的证券购买协议，最多可行使 2 百万股，行使价为每股 6.00 美元。该协议为 EUDA 追求增长计划提供了额外的融资灵活性。
Butterfly Network Inc. (BFLY) 的股价在盘后上涨至 3.21 美元，涨幅为 4.90%。该股在常规交易时段以 3.06 美元平盘收盘。周五没有发布新的公告，但该股的走势反映了盘后交易中的活跃情况。
如有意见和反馈，请联系：editorial@rttnews.com
商业新闻

KYMR

OCUL

POAI

AGPU

几只医疗保健和生物技术股票，包括 Kymera Therapeutics、Ocular Therapeutix 和 Predictive Oncology，在周五的盘后交易中均出现显著上涨。这一势头受到临床更新、近期公告和技术反弹的推动。Kymera 因对临床试验结果的预期上涨了 9.58%，而 Predictive Oncology 在重新获得纳斯达克合规后反弹了 13.62%

Add
<div class="lb-trans">添加
</div><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/>
as your preferred news source on Google
<div class="lb-trans">作为您在 Google 上的首选新闻来源
</div><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/>
Add Now
<div class="lb-trans">立即添加
</div>Several healthcare and biotech names posted notable gains in Friday's after-hours trading session, with momentum driven by clinical updates, recent announcements, and technical rebounds.
<div class="lb-trans">多个医疗保健和生物技术公司在周五的盘后交易中出现显著涨幅，动力来自临床更新、近期公告和技术反弹。
</div>Kymera Therapeutics Inc. (KYMR) surged in extended trading, climbing to $73.00, a 9.58% rise from the close. Shares had ended the regular session at $66.62, up modestly by 0.59%. The company is preparing to announce results from the BroADen Phase 1b clinical trial of KT-621, its oral STAT6 degrader for moderate to severe atopic dermatitis, on Monday, December 8. Anticipation around this readout appears to have fueled strong after-hours momentum.
<div class="lb-trans">Kymera Therapeutics Inc. (KYMR) 在盘后交易中飙升至 73.00 美元，较收盘上涨 9.58%。该股在常规交易时段以 66.62 美元收盘，微幅上涨 0.59%。该公司准备在 12 月 8 日（周一）公布其口服 STAT6 降解剂 KT-621 在中重度特应性皮炎的 BroADen 1b 期临床试验的结果。对这一结果的期待似乎推动了强劲的盘后动能。
</div>Shares of Ocular Therapeutix Inc. (OCUL) advanced to $14.00 after hours, marking an 11.29% increase. The stock closed at $12.58, up 1.21% during the day. While no fresh updates were released on Friday, the company recently announced progress in its HELIOS-3 Phase 3 registrational program for AXPAXLI (OTX-TKI) in non-proliferative diabetic retinopathy, with the first patient randomized on November 24.
<div class="lb-trans">Ocular Therapeutix Inc. (OCUL) 的股价在盘后上涨至 14.00 美元，涨幅为 11.29%。该股在白天以 12.58 美元收盘，上涨 1.21%。虽然周五没有发布新的更新，但该公司最近宣布在非增殖性糖尿病视网膜病变的 AXPAXLI (OTX-TKI) 的 HELIOS-3 3 期注册项目中取得进展，第一位患者于 11 月 24 日被随机分配。
</div>Guardian Pharmacy Services Inc. (GRDN) shares rose to $30.54 in after-hours trading, a 2.62% gain. Shares had closed at $29.76, up 1.50% earlier in the day. The company did not issue new updates on Friday, but the stock extended its upward trajectory into the evening session.
<div class="lb-trans">Guardian Pharmacy Services Inc. (GRDN) 的股价在盘后交易中上涨至 30.54 美元，涨幅为 2.62%。该股在白天以 29.76 美元收盘，上涨 1.50%。该公司周五没有发布新的更新，但该股在晚间交易中延续了上涨趋势。
</div>Predictive Oncology Inc. (POAI) jumped to $4.84 after hours, a 13.62% rise, following a sharp decline during the regular session, where shares fell more than 22% to $4.26. Earlier in the week, the company disclosed that it had regained compliance with Nasdaq's minimum stockholders' equity requirement, ensuring continued listing on the Nasdaq Capital Market. The rebound in extended trading suggests renewed confidence after the compliance update.
<div class="lb-trans">Predictive Oncology Inc. (POAI) 的股价在盘后上涨至 4.84 美元，涨幅为 13.62%，此前在常规交易中大幅下跌，股价跌至 4.26 美元，跌幅超过 22%。本周早些时候，该公司披露已重新符合纳斯达克的最低股东权益要求，确保在纳斯达克资本市场的持续上市。盘后交易的反弹表明在合规更新后信心恢复。
</div>Shares of Acumen Pharmaceuticals Inc. (ABOS) edged higher to $1.92 after hours, up 3.23%. Shares had closed at $1.86, down 6.06% during the day. The company recently presented new research at the Clinical Trials on Alzheimer's Disease (CTAD) conference, highlighting improved delivery of AßO-targeting antibodies through the transferrin receptor pathway. Collaborative work with JCR Pharmaceuticals is now advancing toward clinical testing, supporting long-term development prospects.
<div class="lb-trans">Acumen Pharmaceuticals Inc. (ABOS) 的股价在盘后小幅上涨至 1.92 美元，涨幅为 3.23%。该股在白天以 1.86 美元收盘，下跌 6.06%。该公司最近在阿尔茨海默病临床试验会议（CTAD）上展示了新研究，强调通过转铁蛋白受体通路改善 AßO 靶向抗体的递送。与 JCR Pharmaceuticals 的合作工作正在向临床测试推进，支持长期发展前景。
</div>EUDA Health Holdings Ltd. (EUDA) rose to $2.93 after hours, a 7.72% gain. The stock had closed at $2.72, down 6.85% earlier in the day. On November 26, the company announced a securities purchase agreement with Streeterville Capital for a convertible warrant valued at $100,000, exercisable for up to 2 million shares at $6.00 per share. The agreement provides additional financing flexibility as EUDA pursues growth initiatives.
<div class="lb-trans">EUDA Health Holdings Ltd. (EUDA) 的股价在盘后上涨至 2.93 美元，涨幅为 7.72%。该股在白天以 2.72 美元收盘，下跌 6.85%。在 11 月 26 日，该公司宣布与 Streeterville Capital 达成一项价值 100,000 美元的可转换认股权证的证券购买协议，最多可行使 2 百万股，行使价为每股 6.00 美元。该协议为 EUDA 追求增长计划提供了额外的融资灵活性。
</div>Butterfly Network Inc. (BFLY) gained to $3.21 after hours, up 4.90%. Shares had finished the regular session flat at $3.06. No new announcements were made on Friday, but the stock's move reflects renewed activity in extended trading.
<div class="lb-trans">Butterfly Network Inc. (BFLY) 的股价在盘后上涨至 3.21 美元，涨幅为 4.90%。该股在常规交易时段以 3.06 美元平盘收盘。周五没有发布新的公告，但该股的走势反映了盘后交易中的活跃情况。
</div>For comments and feedback contact: editorial@rttnews.com
<div class="lb-trans">如有意见和反馈，请联系：editorial@rttnews.com
</div>Business News
<div class="lb-trans">商业新闻
</div>

医疗保健公司在盘后交易中表现强劲：Kymera Therapeutics、Ocular Therap、Predictive Oncology 位列涨幅榜前列